Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a public American pharmaceutical company focused on development of treatments for obesity.^[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.^[1] As a public company, Orexigen is publicly listed on the NASDAQ exchange under the stock symbol OREX.^[1]

Orexigen Therapeutics, Inc.

Company type	Public
Traded as	Nasdaq: OREX
Founded	2002; 23 years ago (2002)
Founder	Eckard Weber
Headquarters	La Jolla, California, U.S.
Website	orexigen.com

The company has a single product, Contrave, approved for use in the United States in 2014.^[2][3] Contrave was designed not only to curb hunger but also reduce cravings.^[3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.^{[2][unreliable source?]}

Orexigen declared bankruptcy in 2018 and was sold to Nalpropion.^[4][5]